$NRX Pharmaceuticals(NRXP.US)$ NEWS NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
$NRX Pharmaceuticals(NRXP.US)$NRX Pharmaceuticals (Nasdaq:Nrxp) Receives Notice From Nasdaq That the Company Has Demonstrated Compliance With the Bid Price Requirement
$NRX Pharmaceuticals(NRXP.US)$ NEWS NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to ...
$NRX Pharmaceuticals(NRXP.US)$NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile Infections
$NRX Pharmaceuticals(NRXP.US)$today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101. With data-lock, as forecast in last week's earnings call, the complete data set passed on for statistical analysis; top-line data release expected in April 2024. With positive data from this study and FDA comment, NRx becomes eligible to receive the balance of its first milestone (an additional $4 million) from partners...
$NRX Pharmaceuticals(NRXP.US)$NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression 7 MINUTES AGO, 8:30 AM EDT VIA PR NEWSWIRE • Data transferred for independent statistical analysis • Top-line data expected in April 2024
$NRX Pharmaceuticals(NRXP.US)$PR Newswire RADNOR, Pa., April 1, 2024 Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend -- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. Additions toworking capitalof $8 million in Q1 2024. -- Company forecasts first commercial revenue in 2024 from sales of ke...
NRX Pharmaceuticals股票討論區
NEWS
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
Update
NEWS
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to ...
Update
good run today
good
With positive data from this study and FDA comment, NRx becomes eligible to receive the balance of its first milestone (an additional $4 million) from partners...
Watching
7 MINUTES AGO, 8:30 AM EDT
VIA PR NEWSWIRE
• Data transferred for independent statistical analysis
• Top-line data expected in April 2024
Lots of great info here!
RADNOR, Pa., April 1, 2024
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend
-- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. Additions to working capital of $8 million in Q1 2024.
-- Company forecasts first commercial revenue in 2024 from sales of ke...
暫無評論